Stay updated on Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.

Latest updates to the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.7%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.5%
- Check22 days agoChange DetectedThe web page has been updated from version v2.16.2 to v2.16.3.SummaryDifference0.0%
- Check29 days agoChange DetectedThe page has undergone significant updates, including the removal of specific treatment protocols and drug dosages related to cancer therapies, which may impact the understanding of treatment options available. Additionally, a new revision number has been added, indicating an update to the document.SummaryDifference9%
- Check37 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.7%
- Check44 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.